The medical community was still reeling from the 1999 death of teenager Jesse Gelsinger in an unrelated gene therapy study at Penn. Starting this new research was risky. But Gelsinger had been ...

U.S. gene-therapy research was set back substantially after 18-year-old Jesse Gelsinger, who suffered from an inherited liver disease, died of multiple organ failure in 1999 while participating in ...

David Mack/Photo Researchers, Inc. Since 1998, when 18-year-old Jesse Gelsinger died in a clinical trial at the University of Pennsylvania, the news on gene therapy hasn't gotten much better. In a ...

In 1999, Jesse Gelsinger died of multiple organ failure four days after receiving adenovirus-based therapy for a rare liver disorder. In 2002, a child developed leukemia after receiving retroviral ...

This was the case with 18-year-old Jesse Gelsinger, who in September of 1999 had also traveled to Philadelphia to undergo gene therapy (for the rare condition ornithine transcarbamylase deficiency ...

an 18-year-old gene therapy trial volunteer died. Jesse Gelsinger suffered from ornithine transcarbamylase (OTC) deficiency, an enzyme deficiency that causes an inability to break down ammonia ...